Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Clear cell renal cell carcinoma


Other Names for this Disease

  • Clear cell RCC
  • Clear-cell metastatic renal cell carcinoma (subtype)
  • Cystic-multilocular variant
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

I have read that IL-2 is no longer the standard treatment for metastatic clear cell renal cell carcinoma.  According to the literature, it is no longer used in Europe.  Is this true in North America?  Is sunitinib now prescribed as treatment in North America?

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What treatments for metastatic clear cell renal cell carcinoma are available in North America?

There are several treatments for metastatic clear cell renal cell carcinoma available in North America.  IL-2 and sunitinib - as well as the medications temsirolimus, bevacizumab with interferon therapy, pazopanib, and sorafenib - are approved by the Food and Drug Administration for the treatment of metastatic clear cell renal cell carcinoma.[1]  Because a cure for this disease has yet to be discovered, the National Cancer Institute suggests that individuals with metastatic clear cell renal cell carcinoma consider participation in a research study.[2]

IL-2 is offered as a treatment for this disease in some individuals because it has been shown to cause a complete disappearance of signs of this disease (remission) in 5% of treated patients.[2]  As IL-2 may cause toxic side effects, it is most appropriate for patients who are in excellent health.[1] 

Sunitinib is offered because it has been shown to stabilize metastatic clear cell renal cell carcinoma by stopping the disease from getting worse.  Individuals treated with sunitinib showed no change in their disease for an average of 11 months.[2]
Last updated: 6/1/2012

How can I learn about research involving metastatic clear cell renal cell carcinoma?

The U.S. National Institutes of Health, through the National Library of Medicine, developed ClinicalTrials.gov to provide patients, family members, and members of the public with current information on clinical research studies. Currently, 38 clinical trials are identified as enrolling individuals with metastatic clear cell renal cell carcinoma.  To find these trials, click on the link in the previous sentence. After you click on a study, review its "eligibility" criteria to determine its appropriateness. Use the study‚Äôs contact information to learn more. Check this site often for regular updates.

You can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling 1-800-411-1222 to speak with a specialist, who can help you determine if you are eligible for any clinical trials. If you are located outside the United States, and would like to be contacted via telephone, you will need to contact PRPL and provide your telephone number in full, including area code and international dialing prefix.

Patient Recruitment and Public Liaison Office
NIH Clinical Center
Bethesda, Maryland 20892-2655
Toll-free: 1-800-411-1222
Fax: 301-480-9793
E-mail: prpl@mail.cc.nih.gov
Web site:  http://clinicalcenter.nih.gov/

If you are interested in enrolling in a clinical trial, you can find helpful general information on clinical trials at the ClinicalTrials.gov Web page. Resources on many charitable or special-fare flights to research and treatment sites and low-cost hospitality accommodations for outpatients and family members, as well as ambulance services, are listed on the Web site of the Office of Rare Diseases Research (ORDR), part of the National Institutes of Health.

Last updated: 6/1/2012

References
Other Names for this Disease
  • Clear cell RCC
  • Clear-cell metastatic renal cell carcinoma (subtype)
  • Cystic-multilocular variant
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.